Dementia Drugs Market to Grow with a CAGR of 5.87% through 2030
Advocacy efforts, technological innovations, and global
collaboration are expected to drive the Global Dementia Drugs Market growth in
the forecast period, 2025-2030
According
to TechSci Research report, “Dementia Drugs Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2030F”, the
Global Dementia Drugs Market stood at USD 14.57 billion in 2024 and is
anticipated to grow with a CAGR of 5.87% in the forecast period, 2025-2030.
This can be attributed to Technological Innovations. Advancements in technology
have facilitated the diagnosis and management of dementia. Tools like brain
imaging, biomarker assays, and wearable devices have enabled early detection
and personalized treatment strategies, further fueling the demand for dementia
drugs.
The
collaborative research efforts between pharmaceutical companies, academic
institutions, and government organizations are accelerating drug discovery and
development. The sharing of data, resources, and expertise is fostering a more
collaborative approach to tackling dementia, leading to faster advancements in
drug therapies.
The emergence of the COVID-19 pandemic had a significant impact on the dementia drugs market, leading to notable disruptions in the provision of pharmacological therapy for dementia patients in certain countries. During the pandemic, usage dipped in April and May but rebounded in June. Consequently, COVID-19 had a pronounced impact on market growth. However, since the easing of restrictions, the industry has demonstrated a robust recovery. Over the past two years, this resurgence has been driven by the high prevalence of dementia and the introduction of new product offerings.
The market's growth is being propelled by several key factors, including the escalating incidence of target diseases, the advent of innovative technologies and pharmaceuticals, and increased government funding and awareness initiatives concerning dementia. In line with statistics from the World Health Organization in September 2022, approximately 55 million individuals worldwide were affected by dementia, with over 60% residing in low- and middle-income countries. With the aging population expanding in nearly every nation, this figure is projected to reach 78 million by 2030 and a staggering 139 million by 2050. Consequently, the global surge in dementia cases is expected to be a significant driver of market expansion.
Government funding and awareness campaigns represent pivotal forces behind the market's growth. For instance, as of February 2022, McGill University's Dementia Education Program was among the 15 projects receiving funding from the Public Health Agency of Canada to raise dementia awareness and promote dementia-inclusive communities. In October 2021, the Government of Kerala, India, launched the "Udbodh" program, part of the Dementia-Friendly District initiative, in collaboration with the NeuroScience department at Cochin University of Science and Technology, the Ernakulam district administration, and the Kochi Municipal Corporation.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Dementia Drugs Market”
The Global Dementia Drugs Market is segmented into
indications, drug class, regional distribution, and company.
Based
on Drug Class, Cholinesterase Inhibitors are poised to become the fastest-growing segment in the Global Dementia Drugs Market for several key reasons. These drugs have proven highly effective in managing dementia symptoms, particularly in Alzheimer's disease, by improving cognitive function and memory retention. As the global population continues to age, with a significant portion at risk of developing dementia, the demand for dementia medications is expected to rise steadily, with Cholinesterase Inhibitors being the preferred choice among healthcare professionals. Additionally, ongoing research and development efforts focused on enhancing the efficacy and safety profiles of these inhibitors are likely to further boost their market position. Healthcare providers and regulatory bodies are increasingly recognizing the benefits of Cholinesterase Inhibitors, leading to greater accessibility and broader adoption within dementia treatment protocols. As a result, the rapid growth of this segment is expected to continue, solidifying its dominant role in the Global Dementia Drugs Market for the foreseeable future.
Based
on region, Europe is the fastest-growing region in the global dementia drugs
market due to its aging population, strong government support, and advancements
in drug development. The number of dementia cases is projected to increase by
60% by 2050, significantly driving the demand for effective treatments.
Governments across the region are actively funding research through initiatives
such as the EU Joint Programme – Neurodegenerative Disease Research (JPND) and
national policies in countries like Germany, France, and the UK, which provide
substantial financial support for dementia R&D. Europe has a
well-established clinical trial ecosystem, with pharmaceutical companies
developing innovative therapies and the European Medicines Agency (EMA)
expediting drug approvals, accelerating market expansion. Increasing
public awareness and early diagnosis efforts further support growth, as
improved healthcare infrastructure enables timely intervention and higher
adoption of dementia treatments. The favorable reimbursement policies in many
European countries ensure better accessibility to these treatments, making them
more affordable for patients. This comprehensive approach—combining research
funding, regulatory support, public awareness, and reimbursement
programs—positions Europe as the fastest-growing region in the global dementia
drugs market. As advancements continue, the region is expected to witness
significant developments in dementia treatment and care solutions.
Major companies operating in Global Dementia Drugs
Market are:
·
AstraZeneca PLC
·
Aurobindo Pharma Limited
·
Eli Lilly & Co
·
Johnson & Johnson
·
Pfizer Inc
·
Teva Pharmaceutical Industries Ltd
·
Zydus Lifesciences Ltd
·
Biogen Inc
·
GSK PLC
·
Merck & Co Inc
Download Free Sample Report
Customers can also request for 10% free customization on
this report.
“The
global dementia drugs market is poised for transformation as it responds to the
challenges posed by dementia-related disorders. Emerging trends such as
disease-modifying therapies, early diagnosis, precision medicine, digital
health solutions, immunotherapies, and collaborative research efforts are set
to shape the future of dementia treatment. These trends promise for improved
patient outcomes, enhanced quality of life, and a brighter outlook for
individuals and families affected by dementia. It is essential for healthcare
professionals, researchers, and policymakers to stay informed and actively
engage with these developments to effectively address the growing global
dementia crisis”, said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Dementia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia), By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors), By Region & Competition, 2020-2030F”, has evaluated the future growth potential of Global
Dementia Drugs Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Dementia Drugs
Market.
Contact
TechSci Research LLC
420 Lexington Avenue,
Suite 300, New York,
United States- 10170
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com